Signature Equity Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Signature Equity Partners's REGN Position: Q2 2026 in Review
Signature Equity Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 5 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.
Signature Equity Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.87K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Signature Equity Partners held 5 shares of Regeneron Pharmaceuticals worth $3.12K as of Q2 2026.
- Signature Equity Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
- Regeneron Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1087 holding.
- Signature Equity Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Signature Equity Partners's Regeneron Pharmaceuticals position peaked at $3.87K in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.